The scientists of the French INSERM have identified the enzyme that degrades cholecystocinein, the molecule that controls appetite. This enzyme that flows neurons during intake can be fundamental in therapeutic treatment against volume. However, after the enzyme is injected, other enzymes called peptidase inactivate them.
The effort of Professor Jean-Charles Schwartz and his team is now to identify that the peptidase II tripeptl is the cause of this deactivation. To inhibit this enzyme, the butabanide molecule has been synthesized. Rats have treated this molecule by mouth and the results obtained are encouraging.